NRF2 activation is particularly observed in Type II endometrial cancers, especially serous and clear cell carcinomas, and is associated with increased aggressiveness, poor prognosis, and chemoresistance (104, 106). This evidence concerns the gene NFE2L2 and endometrial cancer.